Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 9/20 | 0.37 |
| ▸ | CDK9 | P50750 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237404 | 0.86 | PDCD1 (0.36) | RENCYP3A4CCNKCDK9KCNH2 | |
| SCHEMBL10186690 | 0.86 | ALDH1A1 (0.36) | KCNH2KDM4EMEN1KMT2ASLC2A1 | |
| SCHEMBL13181404 | 0.83 | PABPC1 (0.35) | RENCYP3A4KCNH2HTTTDP1 | |
| SCHEMBL2635178 | 0.80 | REN (0.44) | RENCYP3A4KDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL4682923 | 0.79 | REN (0.43) | RENCYP3A4KDM4EGAAALDH1A1 | |
| SCHEMBL91265 | 0.78 | REN (0.41) | RENCYP3A4KDM4EHTTALDH1A1 | |
| SCHEMBL660901 | 0.77 | REN (0.41) | RENCYP3A4KCNH2KDM4EMEN1 | |
| SCHEMBL663467 | 0.76 | ALDH1A1 (0.44) | CCNKCDK9KCNH2KDM4EMEN1 | |
| SCHEMBL1751522 | 0.76 | HPGD (0.45) | RENKCNH2 | |
| SCHEMBL664247 | 0.76 | REN (0.42) | RENMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | claimed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | claimed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | claimed |
| EP-1994026-A2 | NEW AMINES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-26 | — | — | EP | claimed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | claimed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | claimed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | claimed |
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 774/4885CCNK 2784/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | REN 1/4885CYP3A4 331/4885CCNK 1446/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885CYP3A4 441/4885CCNK 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.